Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q4 2022

Holdings as of Dec 31, 2022, filed Feb 13, 2023. Long positions only; changes compare share counts with Q3 2022.

Institution overview
Positions
54
+7 vs. Q3 2022
Portfolio value
$218.2M
+$1.25M (+0.6%) vs. Q3 2022
Filed
Feb 13, 2023
SEC
Holdings of Affinity Asset Advisors, LLC in Q4 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
SCLXScilex Holding CoCOM463$1.85K<0.1%+463NewHistory
Medicus Sciences AcquisitionG5960S124*W EXP 02/12/20233,333$2.93K<0.1%00.0%Unchanged–
SCLXWScilex Holding Co*W EXP 11/10/20218,099$3.42K<0.1%+18,099NewHistory
MISTMilestone Pharmaceuticals Inc.COM100,000$396.0K0.2%+100,000NewHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$469.9K0.2%00.0%Unchanged–
NUVBNuvation Bio Inc.COM CL A250,000$480.0K0.2%+250,000NewHistory
INZYInozyme Pharma, Inc.COM500,000$525.0K0.2%+500,000NewHistory
CNTXContext Therapeutics Inc.COM883,654$583.7K0.3%00.0%UnchangedHistory
SGENSeagen Inc.COM5,000$642.5K0.3%+5,000NewHistory
FHTXFoghorn Therapeutics Inc.COM109,991$701.7K0.3%+109,991NewHistory
MIRMMirum Pharmaceuticals, Inc.COM40,000$780.0K0.4%+40,000NewHistory
NRIXNurix Therapeutics, Inc.COM80,000$878.4K0.4%+80,000NewHistory
LIANYLianBioSPONSORED ADS650,000$1.07M0.5%+100,000+18.2%AddedHistory
DYNDyne Therapeutics, Inc.COM92,170$1.07M0.5%+92,170NewHistory
BCABBioAtla, Inc.COM150,000$1.24M0.6%+150,000NewHistory
KALVKalVista Pharmaceuticals, Inc.COM188,292$1.27M0.6%+91,974+95.5%AddedHistory
Esperion Therapeutics Inc Ne29664WAB1NOTE 4.000%11/1–$1.36M0.6%–New–
CNTACentessa Pharmaceuticals plcSPONSORED ADS460,328$1.43M0.7%+217,811+89.8%AddedHistory
Intrexon Corp46122TAA0NOTE 3.500% 7/0–$1.49M0.7%–––
VINCVincerx Pharma, Inc.COM NEW1,492,771$1.52M0.7%00.0%UnchangedHistory
ALPNAlpine Immune Sciences, Inc.COM247,891$1.82M0.8%+137,891+125.4%AddedHistory
ARGXArgenx SESPONSORED ADR5,000$1.89M0.9%+5,000NewHistory
XENEXenon Pharmaceuticals Inc.COM50,000$1.97M0.9%+50,000NewHistory
PNTPOINT Biopharma Global Inc.COM303,218$2.21M1.0%−443,358−59.4%ReducedHistory
COGTCogent Biosciences, Inc.COM193,064$2.23M1.0%+38,977+25.3%AddedHistory
KPTIKaryopharm Therapeutics Inc.COM661,264$2.25M1.0%+661,264NewHistory
IOVAIovance Biotherapeutics, Inc.COM375,000$2.40M1.1%+375,000NewHistory
SNDXSyndax Pharmaceuticals IncCOM100,000$2.54M1.2%+100,000NewHistory
PCVXVaxcyte, Inc.COM60,000$2.88M1.3%+60,000NewHistory
LNTHLantheus Holdings, Inc.Stock60,630$3.09M1.4%−69,370−53.4%ReducedHistory
VKTXViking Therapeutics, Inc.COM350,000$3.29M1.5%+100,000+40.0%AddedHistory
KURAKura Oncology, Inc.COM268,747$3.34M1.5%−407,006−60.2%ReducedHistory
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$3.41M1.6%–––
BridgeBio Pharma, Inc.10806XAD4NOTE 2.250% 2/0–$3.90M1.8%–––
CYTKCytokinetics IncCOM NEW87,601$4.01M1.8%+22,601+34.8%AddedHistory
AZNAstraZeneca PLCSPONSORED ADR60,000$4.07M1.9%−90,000−60.0%ReducedHistory
Bellus Health Inc New07987C204COM NEW573,678$4.72M2.2%+100,081+21.1%Added–
CLDXCelldex Therapeutics, Inc.COM NEW110,000$4.90M2.2%+30,000+37.5%AddedHistory
RCKTRocket Pharmaceuticals, Inc.COM258,115$5.05M2.3%−9,679−3.6%ReducedHistory
HZNPHorizon Therapeutics Public Ltd CoSHS45,000$5.12M2.3%+45,000NewHistory
NARIInari Medical, Inc.Stock90,000$5.72M2.6%−30,000−25.0%ReducedHistory
CERECerevel Therapeutics Holdings, Inc.COM215,000$6.78M3.1%+215,000NewHistory
ATXSAstria Therapeutics, Inc.COM472,482$7.04M3.2%+72,439+18.1%AddedHistory
CBAYCymaBay Therapeutics, Inc.COM1,143,531$7.17M3.3%−146,980−11.4%ReducedHistory
ACLXArcellx, Inc.COMMON STOCK240,143$7.44M3.4%+30,005+14.3%AddedHistory
MORFMorphic Holding, Inc.COM280,921$7.51M3.4%+134,430+91.8%AddedHistory
VTYXVentyx Biosciences, Inc.COM240,623$7.89M3.6%+70,623+41.5%AddedHistory
VRNAVerona Pharma plcSPONSORED ADS312,498$8.17M3.7%−37,502−10.7%ReducedHistory
RXDXPrometheus Biosciences, Inc.COM75,000$8.25M3.8%+50,000+200.0%AddedHistory
BMRNBiomarin Pharmaceutical IncCOM80,000$8.28M3.8%+80,000NewHistory
ASNDAscendis Pharma A/SSPONSORED ADR70,997$8.67M4.0%−29,003−29.0%ReducedHistory
ESTAEstablishment Labs Holdings Inc.COM190,767$12.5M5.7%−135,901−41.6%ReducedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM70,000$20.3M9.3%−30,000−30.0%ReducedHistory
KDNYChinook Therapeutics, Inc.COM818,035$21.4M9.8%+4,037+0.5%AddedHistory

Options (8)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q4 2022
SecurityClassPutsCalls
BMYBristol Myers Squibb CoStock$12.6M–
MRNAModerna, Inc.Stock$5.39M–
AMGNAmgen IncStock$5.25M–
GERNGeron CorpCOM$2.56M$2.03M
VRNAVerona Pharma plcSPONSORED ADS–$2.74M
VKTXViking Therapeutics, Inc.COM–$2.35M
NVAXNovavax IncCOM NEW$2.06M–
NVCRNovoCure LtdORD SHS–$1.83M

Sold out since Q3 2022 (14)

Positions held at the end of Q3 2022 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q3 2022
SecurityClassShares in Q3 2022Value in Q3 2022% of portfolio in Q3 2022History
GBTGlobal Blood Therapeutics, Inc.COM190,000$12.9M6.0%History
SNYSanofiSPONSORED ADR300,000$11.4M5.3%History
Retrophin Inc761299AB2NOTE 2.500% 9/1–$11.1M5.1%–
Nanostring Technologies Inc63009RAD1NOTE 2.625% 5/0–$8.54M3.9%–
SWTXSpringWorks Therapeutics, Inc.COM175,000$4.99M2.3%History
ZNTLZentalis Pharmaceuticals, Inc.COM170,000$3.68M1.7%History
ARYEARYA Sciences Acquisition Corp VCLASS A ORD SHS352,500$3.46M1.6%History
GSKGSK plcADR75,000$2.21M1.0%History
ACRSAclaris Therapeutics, Inc.COM136,434$2.15M1.0%History
NAUTNautilus Biotechnology, Inc.COM372,476$790.0K0.4%History
RCORRenovacor, Inc.COM199,490$503.0K0.2%History
TNGXTango Therapeutics, Inc.COM81,982$297.0K0.1%History
Vickers Vantage Corp IG9440B115*W EXP 09/15/202100,000$17.0K<0.1%–
Renovacor, Inc.75989E114*W EXP 99/99/99975,000$6.00K<0.1%–